363 related articles for article (PubMed ID: 23738843)
1. Phentermine and topiramate extended-release: a new treatment for obesity and its role in a complications-centric approach to obesity medical management.
Garvey WT
Expert Opin Drug Saf; 2013 Sep; 12(5):741-56. PubMed ID: 23738843
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity.
Jordan J; Astrup A; Engeli S; Narkiewicz K; Day WW; Finer N
J Hypertens; 2014 Jun; 32(6):1178-88. PubMed ID: 24621808
[TBL] [Abstract][Full Text] [Related]
3. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
4. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT; Ryan DH; Look M; Gadde KM; Allison DB; Peterson CA; Schwiers M; Day WW; Bowden CH
Am J Clin Nutr; 2012 Feb; 95(2):297-308. PubMed ID: 22158731
[TBL] [Abstract][Full Text] [Related]
5. Combination phentermine and topiramate extended release in the management of obesity.
Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Aronne LJ; Wadden TA; Peterson C; Winslow D; Odeh S; Gadde KM
Obesity (Silver Spring); 2013 Nov; 21(11):2163-71. PubMed ID: 24136928
[TBL] [Abstract][Full Text] [Related]
7. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release.
Guo F; Garvey WT
Diabetes Care; 2017 Jul; 40(7):856-862. PubMed ID: 28455281
[TBL] [Abstract][Full Text] [Related]
8. Phentermine and topiramate extended release (Qsymia™): first global approval.
Cameron F; Whiteside G; McKeage K
Drugs; 2012 Oct; 72(15):2033-42. PubMed ID: 23039320
[TBL] [Abstract][Full Text] [Related]
9. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
10. Phentermine and topiramate for the management of obesity: a review.
Cosentino G; Conrad AO; Uwaifo GI
Drug Des Devel Ther; 2013; 7():267-78. PubMed ID: 23630412
[TBL] [Abstract][Full Text] [Related]
11. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
12. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled study of an oral, extended-release formulation of phentermine/topiramate for the treatment of obstructive sleep apnea in obese adults.
Winslow DH; Bowden CH; DiDonato KP; McCullough PA
Sleep; 2012 Nov; 35(11):1529-39. PubMed ID: 23115402
[TBL] [Abstract][Full Text] [Related]
14. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
15. Combination phentermine and topiramate for weight maintenance: the first Australian experience.
Neoh SL; Sumithran P; Haywood CJ; Houlihan CA; Lee FT; Proietto J
Med J Aust; 2014 Aug; 201(4):224-6. PubMed ID: 25164851
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis.
Lei XG; Ruan JQ; Lai C; Sun Z; Yang X
Obesity (Silver Spring); 2021 Jun; 29(6):985-994. PubMed ID: 33864346
[TBL] [Abstract][Full Text] [Related]
17. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy in Conjunction with a Diet and Exercise Program for the Treatment of Weight Recidivism or Weight Loss Plateau Post-bariatric Surgery: a Retrospective Review.
Schwartz J; Chaudhry UI; Suzo A; Durkin N; Wehr AM; Foreman KS; Tychonievich K; Mikami DJ; Needleman BJ; Noria SF
Obes Surg; 2016 Feb; 26(2):452-8. PubMed ID: 26615406
[TBL] [Abstract][Full Text] [Related]
19. Phentermine/topiramate for the treatment of obesity.
Smith SM; Meyer M; Trinkley KE
Ann Pharmacother; 2013 Mar; 47(3):340-9. PubMed ID: 23482732
[TBL] [Abstract][Full Text] [Related]
20. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Halpern B; Mancini MC
Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]